The Emerging Role of Glucagon-Like Peptide-1 Receptor Agonists for the Treatment of Metabolic Dysfunction-Associated Steatohepatitis
Metabolic dysfunction-associated steatotic liver disease (MASLD) affects an estimated 25-30% of people in the United States and can often progress to Metabolic dysfunction-associated steatohepatitis (MASH) and cirrhosis.
Category
Format
  • Self-study / Enduring
Credits
  • 0.75 ACPE ...See more
  • 0.75 AMA PRA Category 1 Credit™
  • 0.75 ANCC
Cost $0.00